Efficacy and safety of dupilumab in patients with moderate-to-severe atopic dermatitis and comorbid allergic rhinitis

ObjectiveTo examine the efficacy and safety of dupilumab treatment in moderate-to-severe atopic dermatitis (AD) patients with comorbid allergic rhinitis (AR).MethodsA total of 26 patients received subcutaneous dupilumab every 2 weeks and were followed up for 16 weeks. The efficacy assessment was eva...

Full description

Saved in:
Bibliographic Details
Main Authors: Tengfei Tian, Yueguang Li, Guangmei Yuan, Wenxiu Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1556769/full
Tags: Add Tag
No Tags, Be the first to tag this record!